DiaMedica Therapeutics Inc. (DMAC)Healthcare | Biotechnology | Minneapolis, United States | NasdaqCM
6.85 USD
+0.23
(3.474%)
⇧
(April 17, 2026, 3:38 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:20 p.m. EDT
DMAC is a high-risk, high-reward stock with a strong short-term momentum signal due to recent insider buying and positive analyst sentiment. However, the stock's negative fundamentals, including negative earnings and a high short ratio, indicate significant volatility and potential for further declines. While the short-term price movement may offer a buying opportunity, long-term investors should be wary of the company's financial health and uncertain future. The lack of dividends and the speculative nature of the stock make it unsuitable for conservative investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.089989 |
| AutoETS | 0.095676 |
| AutoARIMA | 0.095679 |
| AutoTheta | 0.103278 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 62% |
| H-stat | 1.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.187 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.428 |
| Market Cap | 369,095,136 |
| Forward P/E | -8.19 |
| Beta | 1.15 |
| Website | https://www.diamedica.com |
As of April 11, 2026, 4:20 p.m. EDT: Options speculators are showing mixed signals. Calls have higher open interest and volume for strikes above the current price, suggesting some bullish sentiment for potential upward movement. However, puts also show significant open interest, particularly around the current price, indicating caution or bearish sentiment. The high IV and OI for out-of-the-money calls and puts suggest uncertainty about the stock's direction, with traders hedging against both upward and downward risks. The overall options activity does not strongly indicate a clear trend, and traders should be cautious.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.87535405 |
| Address1 | 301 Carlson Parkway |
| Address2 | Suite 210 |
| All Time High | 44.94 |
| All Time Low | 0.814 |
| Ask | 8.74 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 188,680 |
| Average Daily Volume3 Month | 213,693 |
| Average Volume | 213,693 |
| Average Volume10Days | 188,680 |
| Beta | 1.153 |
| Bid | 5.05 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.044 |
| City | Minneapolis |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.85 |
| Current Ratio | 11.814 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.045 |
| Day Low | 6.675 |
| Debt To Equity | 0.428 |
| Display Name | DiaMedica Therapeutics |
| Dividend Date | 1,542,240,000 |
| Earnings Call Timestamp End | 1,774,958,400 |
| Earnings Call Timestamp Start | 1,774,958,400 |
| Earnings Timestamp | 1,774,900,800 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -34,354,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.647 |
| Enterprise Value | 297,052,192 |
| Eps Current Year | -0.8025 |
| Eps Forward | -0.836 |
| Eps Trailing Twelve Months | -0.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.4332 |
| Fifty Day Average Change | -0.5832 |
| Fifty Day Average Change Percent | -0.07845881 |
| Fifty Two Week Change Percent | 87.53541 |
| Fifty Two Week High | 10.4195 |
| Fifty Two Week High Change | -3.5695004 |
| Fifty Two Week High Change Percent | -0.34257886 |
| Fifty Two Week Low | 3.335 |
| Fifty Two Week Low Change | 3.5149999 |
| Fifty Two Week Low Change Percent | 1.053973 |
| Fifty Two Week Range | 3.335 - 10.4195 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,344,000,600,000 |
| Float Shares | 28,428,410 |
| Forward Eps | -0.836 |
| Forward P E | -8.19378 |
| Free Cashflow | -18,192,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27737 |
| Held Percent Institutions | 0.38472998 |
| Implied Shares Outstanding | 53,882,506 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,542,240,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. |
| Long Name | DiaMedica Therapeutics Inc. |
| Market | us_market |
| Market Cap | 369,095,136 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_4382397 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -32,766,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 356,163,364 |
| Number Of Analyst Opinions | 4 |
| Open | 6.75 |
| Operating Cashflow | -29,062,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 763 496 5454 |
| Previous Close | 6.62 |
| Price Eps Current Year | -8.535826 |
| Price Hint | 2 |
| Price To Book | 6.561302 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.72 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.23000002 |
| Regular Market Change Percent | 3.4743207 |
| Regular Market Day High | 7.045 |
| Regular Market Day Low | 6.675 |
| Regular Market Day Range | 6.675 - 7.045 |
| Regular Market Open | 6.75 |
| Regular Market Previous Close | 6.62 |
| Regular Market Price | 6.85 |
| Regular Market Time | 1,776,454,727 |
| Regular Market Volume | 150,662 |
| Return On Assets | -0.39916 |
| Return On Equity | -0.67678 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 53,882,506 |
| Shares Percent Shares Out | 0.0851 |
| Shares Short | 4,586,548 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,146,534 |
| Short Name | DiaMedica Therapeutics Inc. |
| Short Percent Of Float | 0.1269 |
| Short Ratio | 19.73 |
| Source Interval | 15 |
| State | MN |
| Symbol | DMAC |
| Target High Price | 25.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 15.5 |
| Target Median Price | 13.0 |
| Total Cash | 59,890,000 |
| Total Cash Per Share | 1.111 |
| Total Debt | 240,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.897625 |
| Two Hundred Day Average Change | -0.047625065 |
| Two Hundred Day Average Change Percent | -0.00690456 |
| Type Disp | Equity |
| Volume | 150,662 |
| Website | https://www.diamedica.com |
| Zip | 55,305 |